WEB NEWS Research
CompuMed, Inc. (OTC:CMPD) ($4.09; $5.4M market cap) announced Q4 2025 and full-year results:
Q4 sales of $2,028,284 vs. $1,618,537 in the prior year
Q4 2025 loss per share: ($0.15) vs. EPS of $0.02 in the prior year
FY 2025 sales of $7,546,201 vs. $6,222,018 in FY 2024
FY 2025 loss per share: ($0.05) vs. EPS of $0.15 in FY 2024
Management Commentary
“This performance highlights the resilience of our business model and our ability to adapt to evolving market conditions. EBITDA margin declined during the period, primarily due to higher operating costs, strategic investments to support long-term growth, and one-time third-party professional fees.”
“We have taken significant steps to ensure our leadership team’s interests are directly tied to shareholder success. Following an independent compensation review, the Board issued 400,000 restricted shares to executive officers. These shares do not vest immediately; they are tied to aggressive performance milestones, including stock price targets of $9.00, $12.00, and $15.00 per share. This structure preserves our near-term liquidity while providing a meaningful incentive for long-term value creation, and strengthens the alignment of the executive team and shareholders.”
“As part of our ongoing commitment to strong corporate governance and also given the company’s continued investment in proprietary technology and long-term growth initiatives, the Board adopted a Shareholder Rights Agreement. This measure is intended to protect long-term shareholder value by discouraging coercive takeover tactics and ensuring that the Board has sufficient time to evaluate any proposal that may arise.”
CompuMed, Inc. provides enterprise telemedicine services, including telecardiology, teleradiology, and remote diagnostic solutions that connect medical facilities and patients with board-certified specialists through cloud-based technology.
–
Research
Compumed Inc ( OTC:CMPD) ($2.51; $4.1M market cap) - On Monday, CMPD, the go-to provider of clinical organ analysis, offering rapid diagnostic reads by industry-best expert physicians through a seamless platform and process, announced it will integrate the Techcyte Digital pathology reviewing platform to help increase transplanted organs.
Techcyte, Inc.is the world leader in AI-based cellular digital diagnostics.
"CompuMed's collaboration with Techcyte signifies a pivotal moment in the field of transplantation, offering the promise of better organ graft evaluation and higher success rates," says Lee Keddie, CEO of CompuMed. "By leveraging technology to enhance the assessment of transplant organs, this collaboration aims to reshape the landscape of organ transplantation, allowing quicker, more accurate decisions, increasing the organs transplanted, and ultimately, saving more lives."
We added CMPD to our Run to One Model Portfolio in December of 2019 (prior to 1 for 25 split in May 2022). The company’s progress has been slow, and notable top line growth has yet to be achieved. We have been waiting for the company to explore ways to expand its telemedicine business outside its core service offering. It’ll be interesting to see if this new technology partnership can begin to drive top and bottom line growth.
Research
Compumed Inc ( OTC:CMPD) ($1.82; $3.4M market cap) , an enterprise telemedicine solutions company that provides clinical care services for patients and medical facilities, announced the purchase of shares held by VI Capital Fund which David Pointer (Director of CMPD) and Lee Keddie (CEO of CMPD) are investors in. The company purchased 425,403 shares or 25.3% of the outstanding shares for $2.00 per share.
“Both David Pointer and Lee Keddie are investors in the Fund. Mr. Keddie is the CEO of CompuMed and both he and Mr. Pointer are Directors of CompuMed. Both Mr. Keddie and Mr. Pointer recused themselves from the Corporation's decision to offer $2.00 per share for shares held by the Fund.”
CMPD plans to retire the shares.
Research
Compumed Inc ( OTC:CMPD) ($0.18; $7.7M market cap), an enterprise telemedicine solutions company that provides clinical care services for patients and medical facilities, announced Q2 2022 results:
Sales of $1.59 million vs $1.63 million in the prior year
Net profit of $38,994 vs net profit of $143,900
EPS of $0.00 vs $0.00
“At March 31, 2022 CompuMed enjoyed a cash + accounts receivable position of $2.6 million, down 7.0% from December 31, 2021 down 8.5% from one year ago. Over the past several quarters we have meaningfully reduced outstanding lease balances, have increased our equipment portfolio, and have maintained our cash levels with the investments made in technology.
Please note, CompuMed has not utilized the majority of the previously disclosed $1 million share buyback authorization.”
Research
Compumed Inc ( OTC:CMPD) ($0.29; $8.3M market cap), an enterprise telemedicine solutions company that provides clinical care services for patients and medical facilities, announced Q1 2022 results:
Sales of $1.54 million vs $1.47 million in the prior year
Net profit of $121,000 vs net profit of $108,000
EPS of $0.00 vs $0.00
In its Q4 2021 release, the company announced several corporate actions that will be voted on during the annual meeting on March 15, 2022, including a reverse stock split of 1 for 25 and the elimination of preferred stock.
